BMO Capital Weighs in on ARIAD Pharmaceuticals (ARIA) Following Abstracts at AACR
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough reiterated a Outperform rating and $14 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) after abstracts ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
